Cytox Awarded New Innovate UK Funding for Alzheimer’s Testing
Cytox , an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, is pleased to announce that, in partnership with Cardiff University, the company has been awarded funding by Innovate UK. The award is £800,000 ($1.3m) out of a total project value of £1m ($1.6m) over two years.
The project will evaluate and validate the clinical utility of a customised SNP (single nucleotide polymorphism) panel associated with the development of Alzheimer's disease (AD). The team comprises Professors Valentina Escott-Price and Julie Williams of Cardiff University and Cytox.
“We are delighted to be awarded further funding by Innovate UK,” commented Dr Richard Pither, CEO of Cytox, “The previous award has enabled support for projects to date, and the subsequent commercialisation has been pivotal to the growth of the company. This new funding reaffirms the validity of our approach in this highly important area. We are also pleased to be collaborating with Cardiff University. We have been working with Professor Escott-Price as our AD statistical expert for a few years now, and welcome Professor Julie Williams, who is of course pre-eminent in the field of Alzheimer’s disease genetics research and currently one of the four leaders of the IGAP genetics consortium.”
Mild cognitive impairment (MCI) may be a prodromal state for AD and 50-60% of these patients are at high risk of progression to AD, however current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of these patients and also the development of new therapies. The project will develop, optimise and test a set of polygenic risk score (PRS) approaches and then implement them on Cytox's own proprietary software platform. Subsequently the algorithms will be tested in large cohorts of patients and cognitively normal subjects, such as the recently well characterised 500 patient subset of the 1946 birth cohort, to demonstrate the validity of a panel of identified at-risk AD biomarkers. The project aim is to confirm that a proprietary SNP panel and associated algorithm is an effective method for predicting the presence of AD pathology. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
TX-VIKING-ACQUISITION22.6.2018 13:11 | pressemeddelelse
Announcement by Viking Corp on Tecnotree
TX-HEARTSCIENCES22.6.2018 13:02 | pressemeddelelse
HeartSciences Named “Start-Up to Watch”
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum